However, in co-cultures with CML cells from most HR patients the IL-2 concentration in the medium was decreased after addition of blocking antibody implicating that the PD-1/PD-L1 interaction may have different function in these patients. The gene discussed is IL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.